Dostarlimab (Jemperli, GSK) is indicated 'in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI‑H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy'.
The dosage schedule is available in the summary of product characteristics for dostarlimab.
The company has a commercial arrangement (simple discount patient access scheme). This makes dostarlimab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.